Fill in the form below and our experts will get back to you within 1 business day.
Endotoxin-free, high-yield protein production powered by the GRAS-status bacterium with superior secretion capability. From milligram to multi-gram scale.
Trusted by leading research and pharmaceutical institutions
No LPS contamination
Direct export to medium
FDA recognized safe
Leverage the power of Bacillus subtilis - the ideal Gram-positive expression host with natural secretion capability, endotoxin-free production, and proven high yields.
No lipopolysaccharide (LPS) contamination. Unlike E. coli, B. subtilis naturally produces proteins without endotoxins, simplifying downstream purification and reducing costs.
Direct protein secretion into culture medium. Avoids cytoplasmic aggregation and inclusion body formation common in E. coli systems.
FDA recognized safe for food and pharmaceutical applications.
Up to 50% of total cellular protein expression levels.
Pgrac, T7-based, secretion, and genome integration.
From 5 mL screening to 1000 L industrial production.
Get a customized quote for your project. Our team will respond within 24 hours.
Multiple expression systems optimized for high-level protein production.
Strong IPTG-inducible promoters with tight regulation. Expression levels up to 50% of total cellular protein with excellent induction ratios.
Phage T7 RNA polymerase-driven expression for maximum transcriptional activity. Ideal for high-level protein production with SCK22 host strain.
Multiple signal peptides (AmyQ, SP-lip, AprE) for efficient protein translocation. Direct secretion into medium simplifies purification.
Stable chromosomal integration for toxic proteins or long-term production. No antibiotic selection required for stable expression.
Comprehensive specifications to meet your production requirements.
| Parameter | Specification |
|---|---|
| Expression Systems | Pgrac (IPTG-inducible), T7-based, Constitutive, Secretion |
| Host Strains | WB800N, 168, 1012, Custom strains |
| Protein Size | Up to 150 kDa |
| Expression Level | Up to 50% of total cellular protein |
| Purity | >95% (multi-step chromatography) |
| Endotoxin | <1 EU/mg (therapeutic grade available) |
| Purification Tags | 6xHis, Strep-tag II, GST, MBP, SUMO |
| Delivery Format | Lyophilized powder or solution |
| Scale | mg to multi-gram (5 mL to 1000 L) |
Our proven 5-step workflow ensures quality and efficiency at every stage.
Codon optimization and vector construction
Host strain selection and transformation
High-throughput clone selection
Optimized fermentation and expression
Multi-step chromatography and QC
Our expression services support research and development in multiple fields.
B. subtilis is the preferred host for industrial enzyme production, accounting for over 60% of commercially available enzymes. Our expression system delivers high yields with excellent activity retention.
The GRAS status and endotoxin-free nature of B. subtilis make it ideal for producing therapeutic proteins that require high purity and minimal contamination.
Fast, reliable protein production for structural biology, biochemical studies, and drug discovery research. Flexible scale from mg to gram quantities.
Trusted by researchers worldwide for quality and reliability.
"Switching from E. coli to this B. subtilis platform was a game-changer. Our enzyme showed much higher activity and required minimal downstream processing. Highly recommended!"
"The secretion capability saved us weeks of work. Protein came out directly into the medium - we went from culture to purified sample in record time. Professional service!"
"We've used this service for multiple therapeutic protein projects. Consistent quality and professional support every time. Our go-to provider for B. subtilis expression."
Our platform is backed by peer-reviewed research.
Dinh Thi Minh Tran, Trang Thi Phuong Phan, Thanh Thi Ngoc Doan, et al. Biotechnology Reports. 2020.
Development of Pgrac promoter-based integrative expression vectors enabling high-level protein production without inducer addition in B. subtilis.
Yang W, Zhang J, Chen F, Li H, et al. Bioresources and Bioprocessing. 2022.
Development of a T7-based expression system in B. subtilis achieving 25-40% total protein expression with excellent scalability.
Yao ZY, Yu MJ, Li QQ, et al. ACS Synthetic Biology. 2024.
Dual-module T7 integration system for high-yield protein production without antibiotics or inducers, achieving 6.86 g/L hyaluronic acid.
Fu G, Yue J, Li D, et al. Proceedings of the National Academy of Sciences. 2022.
MATE expression toolkit enabling precise gene expression regulation with up to 790-fold induction for synthetic biology applications.
Knöfler L, Pogrebnya A, Mücksch L, et al. ACS Synthetic Biology. 2024.
Characterization of genome-reduced B. subtilis strain with 26.1% genome deletion showing superior performance for heterologous protein secretion.
Find answers to common questions about our B. subtilis expression service.
Get a customized quote for your Custom Bacillus subtilis Expression Service project. Our experts will respond within 24 hours.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.